by David Eyre | Jan 1, 2016 | US & International
Executive Summary / Practice Points Stem cell technologies promise to be the next transformative medical technology offering therapies for conditions and diseases that are currently beyond medical science by creating replacement or supplementary tissues for a patient....
by David Eyre | Jan 1, 2016 | US & International
The origin of the PTE system flows from a desire to compensate those who have invested time and resources in making or finding new medical products for the additional burden of gaining regulatory approval for that product. Thus, originally, the PTE provisions were...
by David Eyre | Aug 1, 2014 | UK, US & International
Biopiracy is the evil sibling of bioprospecting. Bioprospecting is the search for existing genetic resources and biological knowledge that can be applied more widely and in novel applications. This is an area of particular interest to the pharmaceutical industry...
by David Eyre | Apr 1, 2014 | Briefings, US & International
Therefore, applicants may wish to consider filing any available complete applications and national phase entry applications in New Zealand prior to 13 September 2014 in order to not only avoid the more stringent patentability requirements of the New Act but also to...
by David Eyre | Apr 1, 2014 | US & International
Selected points of interest are as follows: New regulations to streamline and clarify existing procedures. This is done through detailing e filing provisions, introducing the “division of trade mark applications” for partially refused applications,...
by Dr Andrew Clements | Jan 1, 2013 | US & International
A central issue was whether it was appropriate, when considering whether a claim was obvious, to apply the so-called “teaching, suggestion or motivation” (TSM) test. The Supreme Court decided that the TSM test provides a “helpful insight” but criticised the lower...
Recent Comments